A Medicxi-backed start­up looks to tack­le treat­ment-re­sis­tant blood can­cers, and it's go­ing af­ter AML first

In the hard­est-to-treat blood can­cers, re­sis­tance to ther­a­py is an ex­is­ten­tial prob­lem for drug de­vel­op­ers look­ing to per­ma­nent­ly stave off tu­mors. A small biotech is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER